Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

7,600.00ILa
23 May 2018
Change (% chg)

60.00 (+0.80%)
Prev Close
7,540.00
Open
7,500.00
Day's High
7,600.00
Day's Low
7,409.00
Volume
488,050
Avg. Vol
807,658
52-wk High
11,850.00
52-wk Low
3,820.00

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 1.24
Market Cap(Mil.): ₪65,841.12
Shares Outstanding(Mil.): 1,014.36
Dividend: 30.51
Yield (%): 6.31

Financials

  TEVA.TA Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -21.22 -- --
ROI: -10.61 14.84 14.38
ROE: -24.14 16.34 16.07

Teva hopes to launch migraine drug as soon as September

JERUSALEM Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay.

23 May 2018

UPDATE 1-Teva hopes to launch migraine drug as soon as September

JERUSALEM, May 23 Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay.

23 May 2018

Teva Pharm says FDA to decide on migraine drug on Sept 16

JERUSALEM, May 23 Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay.

23 May 2018

Berkshire Hathaway doubles Teva bet, confirms Apple purchases

May 15 Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest shareholder.

16 May 2018

BRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic Emulsion

* TEVA CANADA ANNOUNCES THE LAUNCH OF TEVA-CYCLOSPORINE® OPHTHALMIC EMULSION, THE FIRST GENERIC VERSION OF RESTASIS® IN CANADA FOR THE TREATMENT OF DRY EYE DISEASE

10 May 2018

UPDATE 2-Teva raises 2018 outlook, expects migraine drug approval by year-end

* Teva's North American generic product sales down 23 pct (Adds comments from CEO interview, conference call, analyst quote)

03 May 2018

BRIEF-Teva Reports Q1 Non-GAAP Earnings Per Share $0.94

* RESTRUCTURING PLAN ON-TRACK TO ACHIEVE $1.5 BILLION OF SAVINGS IN 2018 AND $3.0 BILLION BY END OF 2019

03 May 2018

Teva Pharm Q1 profit down less than forecast, raises 2018 outlook

TEL AVIV, May 3 Israel's heavily indebted Teva Pharmaceutical Industries reported a smaller than-expected drop in first-quarter net profit on Thursday and raised its forecast for full-year earnings.

03 May 2018

Teva Pharma opts to maintain Israeli logistics centre

* Teva Pharmaceutical Industries said on Wednesday it had decided not to sell its SLE logistics centre in Israel.

02 May 2018

BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml

* TEVA PRESENTS NEW LONG-TERM DATA DEMONSTRATING EFFICACY AND SAFETY OF COPAXONE (GLATIRAMER ACETATE INJECTION) 40 MG/ML

28 Apr 2018

Earnings vs. Estimates